What Lasa Treats: Main Uses and Benefits

Lasa is used to manage symptoms linked to specific medical conditions. Its primary function is providing relief for associated symptoms, which may assist in coping with daily activities. The medication is indicated for conditions where symptom control is necessary, including mild to moderate anxiety, certain sleep disturbances, and situational nervous tension.

Quick Fact: Relief for Situational Nervous Tension

Clinical use commonly involves the temporary management of acute stress reactions or as a supplemental therapy for generalized unease. The benefit to patients is focused on symptom relief to support overall well-being.

Who Can and Cannot Use Lasa (Famotidine)

Lasa (Famotidine) eligibility is defined by regulatory agencies based on specific population characteristics and health conditions.

---

Contraindicated Populations

• The medicine is strictly contraindicated for patients with a documented history of serious hypersensitivity reactions, such as anaphylaxis, to famotidine or to any other medicine in the Histamine H₂-receptor antagonist class.

---

Age-Related and Organ Function Eligibility

• Use is generally permitted in adult patients and pediatric patients one year of age and older for prescription uses.
• Specific oral tablet strengths are not recommended for children weighing less than 40 kg.
• Older adults require caution and monitoring of renal function, as decreased kidney function is more likely in this population.

---

Conditional Use Status

• Patients with moderate or severe renal impairment (creatinine clearance below 60 mL/min) must have their dosage adjusted due to slower drug clearance and an increased risk of Central Nervous System effects.
• Use during pregnancy is restricted and recommended only if clearly needed, due to a lack of established human safety data.
• The medicine does not preclude the presence of an underlying gastric malignancy, and evaluation should be considered prior to use.

Interactions with other medicines and products — official regulatory information for Lasa

Interaction scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions	Drugs whose absorption is sensitive to gastric pH (e.g., Azole antifungals, certain Tyrosine Kinase Inhibitors); drugs cleared by CYP1A2 metabolism (e.g., Tizanidine); and substances that affect absorption (e.g., Sucralfate, Antacids) or renal clearance (e.g., Probenecid).
Specific interacting medicines	Tizanidine, Probenecid, Ketoconazole, Itraconazole, Erlotinib, Dasatinib, Pazopanib, Antacids, Sucralfate.
Mechanistic basis of interactions	Pharmacokinetic interaction via Altered Gastric pH (reducing absorption of co-administered drugs); Pharmacokinetic interaction via CYP1A2 enzyme inhibition (reducing metabolic clearance); Pharmacokinetic interaction via Inhibition of Renal Tubular Secretion (reducing Famotidine clearance).
Timing-based interaction rules	Sucralfate should not be administered within 2 hours of the Lasa dose to prevent reduced Famotidine absorption. Antacids may be considered for administration one to two hours before Lasa for the same reason.
Population-specific interaction notes	Renal Impairment: Patients with moderate to severe impairment may experience higher systemic exposure of Famotidine due to reduced clearance, which can increase the severity of dose-dependent interactions. Elderly Patients (65+): May have an increased risk for certain adverse reactions linked to generally higher blood concentrations of the drug.
Interaction-related restrictions	Co-administration with certain Tyrosine Kinase Inhibitors (e.g., Dasatinib) is not recommended. The use of Lasa with Tizanidine warrants caution due to the risk of substantially increased Tizanidine blood concentrations.

---

Interaction classifications (high-level)

Category	Official Regulatory Documentation
Interaction severity classification	Clinically Significant Interactions (reduced efficacy or increased toxicity of co-administered drugs); Use-with-Caution/Timing Constraint (e.g., Sucralfate, Antacids).
Regulatory basis	US Food and Drug Administration (FDA) Prescribing Information; European Medicines Agency (EMA) Summary of Product Characteristics; National Institutes of Health (NIH) regulatory data.
Interaction-context constraints	Lasa is officially documented to not interact with the general CYP P450 system (except for the specific CYP1A2 inhibition of Tizanidine). Interactions with food and alcohol are formally stated to be not clinically significant.

---

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product's interaction structure primarily through two types of pharmacokinetic interference: altering gastric acidity to affect the absorption of other medicines, and specific enzyme/transporter inhibition to affect the clearance of both co-administered drugs and Famotidine itself. The profile formally classifies substances requiring mandatory separation in time and identifies a crucial CYP1A2 metabolic interaction with Tizanidine. The official regulatory record also establishes the non-significance of interactions with food and alcohol.

Famotidine acts exclusively at the molecular and cellular level to modulate a specific pathway of stomach acid production, which leads to a defined physiological change.

Targeting the Histamine H2-Receptor

Famotidine is classified as a competitive antagonist that primarily targets the Histamine H2-receptors located on the gastric parietal cells. By binding to these receptors, the molecule physically prevents the natural chemical messenger, Histamine, from stimulating the cell. This action is the initial molecular step that defines the drug's mechanism of acid suppression.

Interrupting the Acid Secretion Cascade

The receptor blockade immediately interrupts the normal intracellular signaling pathway. This action blocks the Histamine-mediated increase in cyclic AMP (cAMP), which in turn diminishes the activation of the final acid-secreting machinery—the Proton Pumps. This mechanism involves the modulation of processes driven by this distinct signaling pattern, leading to a decrease in the cell's capacity to release hydrogen ions ( H^+).

Suppression of Gastric Fluid Acidity

The cumulative result of these molecular and cellular actions is the reduction in the overall volume and concentration of acid in the stomach contents. This physiological change affects both the basal (continuous, resting) and stimulated (meal-induced) acid secretion, resulting in a systematically less acidic gastric environment. However, the mechanism's influence is primarily limited to the Histamine-driven pathway.

How Lasa (Famotidine) is Used in Practice

Lasa, which contains the active ingredient Famotidine, is administered according to specific procedural guidelines. The primary method of intake is the oral route via tablets or oral suspension for general use. However, the medicine is also formulated as a solution for injection to be administered intravenously (IV), a route generally reserved for short-term use in hospitalized patients who cannot tolerate oral medication.

Official Dosing and Administration Parameters

Administration frequency and dosage quantity are dependent on the specific condition addressed. For example, the typical regimen for active duodenal or gastric ulcers is 40 mg taken once daily at bedtime or 20 mg twice daily. In contrast, patients with pathological hypersecretory conditions may begin with 20 mg every six hours, with doses potentially increasing up to 160 mg every six hours.

Parameter	Official Instruction Summary
Timing with Food	May be taken with or without food.
Course Duration	Ranges from 6 to 12 weeks for active conditions; maintenance therapy may extend up to one year.
IV Administration	Must be administered slowly, taking at least two minutes for injection or infused over 15 to 30 minutes.
Renal Adjustment	For adults with moderate to severe kidney impairment, the dosage must be reduced by 50% or the interval between doses extended to 36–48 hours to prevent accumulation.

Specific preparation requirements apply to the liquid form: the oral suspension must be reconstituted with water and then shaken vigorously prior to each use. Pediatric patients are subject to weight-based dosing requirements.

Research Evidence: Overview of Studies for Lasa (Famotidine)

Evidence for Acute Conditions

Research into Lasa for active duodenal and gastric ulcers primarily consists of short-term, randomized controlled trials (RCTs) involving adult outpatients. These studies examined how symptoms evolved and investigated endoscopic outcomes, such as the time until a reported change in pain and the percentage of endoscopically-assessed healing observed, typically over observation periods lasting four to eight weeks.

Studies for erosive esophagitis and general symptomatic non-erosive gastroesophageal reflux disease (GERD) utilized controlled trials to evaluate tissue status and symptom monitoring. For tissue damage, studies examined the status of esophageal erosions, with outcomes measured over periods of 6 to 12 weeks. For GERD symptoms, research focused on short-term changes, monitoring patient-reported outcomes related to the frequency and intensity of heartburn.

Maintenance and Prophylactic Research

Intermediate-term, placebo-controlled maintenance RCTs explored Lasa's application for individuals with previously healed ulcers. These studies monitored the incidence of ulcer recurrence, confirmed by endoscopy over observation periods that lasted up to one year. Additionally, research examined its evaluation in prophylaxis settings, such as in adults taking low-dose aspirin, where trials were designed to measure the development of new ulcers over a 12-week interval. Research also included pediatric patients experiencing GERD symptoms and older adults in various subgroup analyses.

Gaps and Areas of Uncertainty

A central limitation is that the long-term effects are not fully established for continuous observation extending beyond 6 to 12 months for most non-maintenance indications; follow-up durations were often limited. Data for certain groups, such as those with unique comorbidities or specific geriatric subsets, remain insufficient. Furthermore, the scope of controlled studies against all available treatment types shows heterogeneity, and findings were mixed regarding outcomes in specific subgroups, such as smokers in maintenance trials. This research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. NIH MedlinePlus Drug Information: Famotidine (oral route)

Common questions about Lasa (FAQ)

---

Q: Is Lasa considered a long-term or short-term treatment?

Official documents describe Lasa's use in short courses (e.g., 6 to 12 weeks) for treating active conditions. However, the regulatory label also permits its use in maintenance therapy for certain conditions, which may be extended up to one year to help prevent recurrence.

---

Q: Can Lasa be taken with my regular vitamins or supplements?

Official product information focuses on interactions with specific prescription medicines. While the drug is stated to have no clinically significant interactions with food, the recommendation is to inform a healthcare provider of all supplements being taken.

---

Q: Does Lasa cause tiredness or make you drowsy?

Regulatory documents include fatigue (tiredness) and somnolence (drowsiness) among reported side effects, though they are listed as infrequent adverse reactions. These effects are observed in some patients but are not among the most common adverse effects.

---

Q: Is Lasa safe to use for older adults?

According to official product information, the use of Lasa is generally permitted for older adults. However, official information indicates caution may be necessary due to the potential for an increased risk of specific side effects, such as confusion or hallucinations (CNS effects), often linked to potential changes in kidney function.

---

Q: Is Lasa safe to use for children?

The regulatory label confirms Lasa is approved for use in pediatric patients one year of age and older for certain prescription uses. Eligibility is restricted by weight-based dosing requirements, and some tablet strengths are not recommended for children weighing less than 40 kg.

---

Q: Does Lasa need to be taken at a specific time of day?

The requirement for taking Lasa at a specific time of day depends on the medical condition being treated. For example, some official regimens are described as being taken once daily at bedtime or twice daily. Dosage frequency and timing are determined based on the specific condition being treated, and are guided by a healthcare provider.

---

Q: What is the shelf life of Lasa?

Official storage guidelines require the tablets to be kept at a temperature not above 25 C and protected from light and moisture. The stability of the reconstituted oral suspension is limited, and it must be discarded after 30 days.

---

Q: Is Lasa safe for people with kidney disease?

Official documents state that Lasa can be used by people with kidney impairment, but only under specific conditions. Official guidelines recommend dosage adjustments, such as a reduced dose or an extended interval, for adults with moderate to severe kidney impairment to minimize accumulation.

---

Q: Can Lasa affect my ability to drive or operate machinery?

The official label includes a warning that some patients may experience side effects, such as dizziness or fatigue. These effects could potentially impair the ability to safely drive or operate heavy machinery.

---

Q: Can Lasa cause changes in mood or behavior?

The drug's label notes that there is a risk of specific Central Nervous System (CNS) adverse reactions, such as confusion and hallucinations. This risk is particularly noted in elderly patients and those who have kidney problems.

---

Q: What does the term 'contraindication' mean in relation to Lasa?

A contraindication is a regulatory term for a specific condition or circumstance that officially makes a drug's use prohibited due to high safety risks. In the case of Lasa, this includes a documented history of a serious hypersensitivity (allergic) reaction to the medicine or other drugs in the same class.

---

Q: Does Lasa require regular blood tests or monitoring?

Regulatory documents indicate that renal function monitoring may be required for older adults. Furthermore, reports of liver enzyme abnormalities have been noted as adverse reactions. The need for specific blood tests or monitoring is determined by a healthcare provider based on the patient's individual health status.

---

Q: What is the main difference between Lasa and other similar medicines?

Lasa is officially classified as a Histamine H2-receptor antagonist (H2-blocker). The regulatory label highlights this classification and includes a contraindication for individuals with hypersensitivity to other medicines within this same H2-blocker class.

---

Q: How quickly should I expect to feel the effects of Lasa?

Studies and official information indicate that Lasa typically begins its acid-suppressing effect within the first hour after an oral dose.

---

Q: Does Lasa work immediately after taking the first dose?

Official information indicates that the drug begins its acid-reducing effect within the first hour of administration.

---

Q: Is Lasa safe to use while breastfeeding?

Regulatory documents state that Lasa is excreted in human milk. Official guidance indicates a healthcare provider should assess whether to discontinue nursing or discontinue the drug, taking into account the mother's therapeutic need.

---

Q: How long does Lasa stay in your system after the last dose?

The regulatory label lists the plasma half-life of the drug as approximately 2.5 to 3.5 hours in patients with normal kidney function. The half-life value provides an estimate of the rate at which the drug’s concentration is reduced in the body.

---

Q: Are there generic versions of Lasa available?

Official documents confirm that Lasa's active ingredient, Famotidine, is widely available as an approved generic product.

---

Q: Is Lasa a controlled substance?

According to regulatory agencies, Lasa is formally classified as a non-controlled substance.

---

Q: Does Lasa affect the results of any common medical tests?

Official regulatory documents may list potential interference with certain diagnostic tests, such as tests that measure gastrin or other acid-related substances in the body, due to the drug's effect on stomach acid.

---

Q: What is the purpose of the black box warning on Lasa, if applicable?

Official regulatory documents indicate that Lasa does not carry a mandatory Boxed Warning (often called a Black Box Warning) in its standard formulation.

---

Q: What makes Lasa different from natural supplements for the same purpose?

Official product information defines Lasa as a synthetic pharmaceutical agent and classifies it as a Histamine H2-receptor antagonist. This classification provides its chemical origin and precise regulatory identity, distinguishing it from natural products.

---

Q: What information about Lasa is required on the official label?

The official label requires specific sections of information, including Dosing and Administration, Warnings, Adverse Reactions, and Patient Information. This structured format ensures that a minimum standard of factual information is provided to both healthcare providers and patients.

The official storage and disposal requirements for Lasa (Famotidine) are defined by the pharmaceutical form to ensure product stability and patient safety.

Official Storage Conditions

Dosage Form	Temperature/Environment Rule
Tablets	Must be stored in the original package at a temperature not above 25 C to protect from light and moisture (UK SmPC).
Oral Suspension	Store at 25 C (77 F) and must be strictly protected from freezing (FDA).

Stability and Child Safety

The reconstituted oral suspension has a limited shelf life and must be discarded after 30 days. All forms of Lasa must be stored out of the sight and reach of children (NIH MedlinePlus).

Disposal

Disposal of unused or expired product must be done in accordance with local requirements (UK SmPC). For at-home disposal of non-flushable medicines, mixing the product with an undesirable substance (e.g., dirt, coffee grounds) and placing it in a sealed container for household trash is advised (FDA).